Clinical Trials Logo
  1. Home
  2. Beta Thalassemia Major
  3. NCT03101423

Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

Beta Thalassemia Major Clinical Trial

Official title:
Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

Clinical Trial Summary

Hematopoietic stem cell transplantation is currently the only way to cure thalassemia, one of its main obstacles is the rejection after transplantation, chimerism continued to decline, which eventually lead to transplant failure. chimerism is a key indicator of the succession of immune response, which is a key indicator for predicting the failure of hematopoietic stem cell transplantation and provides an important basis for early detection of rejection. Transplantation of continuous chimerism can detect early unstable chimeras and rejection.The chimerism rates after transplantation were continuously monitored using fluorescence labeled multiplex PCR amplification of short tandem repeats (STR-PCR)

,and then follow our STR different rates for early interventional therapy to prevent further reduction in chimerism leading to lead to graft failure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03101423
Study type Interventional
Source First Affiliated Hospital of Guangxi Medical University
Contact
Status Active, not recruiting
Phase N/A
Start date August 1, 2016
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03276455 - Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified Phase 1/Phase 2
Completed NCT02674607 - the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children N/A
Terminated NCT01571635 - Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. Phase 2
Completed NCT04092205 - Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation Phase 2
Completed NCT02744560 - Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C N/A
Recruiting NCT04353986 - PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Phase 3
Not yet recruiting NCT02173951 - An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Phase 2/Phase 3
Completed NCT03947632 - Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia
Withdrawn NCT04776850 - Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Early Phase 1
Completed NCT02744105 - Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C N/A
Completed NCT02744547 - Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C N/A
Completed NCT02671695 - Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia N/A
Completed NCT00658385 - Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major N/A